TCM Biotech International Past Earnings Performance
Past criteria checks 3/6
TCM Biotech International's earnings have been declining at an average annual rate of -10.3%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 10.5% per year. TCM Biotech International's return on equity is 1.8%, and it has net margins of 1.9%.
Key information
-10.3%
Earnings growth rate
-11.2%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 10.5% |
| Return on equity | 1.8% |
| Net Margin | 1.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Can You Imagine How TCM Biotech International's (GTSM:4169) Shareholders Feel About The 28% Share Price Increase?
Jan 31
Key Things To Consider Before Buying TCM Biotech International Corp. (GTSM:4169) For Its Dividend
Jan 04We Think TCM Biotech International (GTSM:4169) Can Stay On Top Of Its Debt
Dec 07
Revenue & Expenses BreakdownBeta
How TCM Biotech International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 970 | 19 | 380 | 77 |
| 30 Sep 23 | 932 | 16 | 377 | 77 |
| 30 Jun 23 | 895 | 13 | 374 | 77 |
| 31 Mar 23 | 849 | 16 | 358 | 80 |
| 31 Dec 22 | 802 | 18 | 341 | 82 |
| 30 Sep 22 | 761 | 13 | 321 | 79 |
| 30 Jun 22 | 720 | 8 | 300 | 77 |
| 31 Mar 22 | 711 | 5 | 288 | 79 |
| 31 Dec 21 | 702 | 2 | 276 | 80 |
| 30 Sep 21 | 694 | -2 | 270 | 83 |
| 30 Jun 21 | 686 | -5 | 264 | 86 |
| 31 Mar 21 | 712 | 10 | 262 | 79 |
| 31 Dec 20 | 737 | 26 | 260 | 72 |
| 30 Sep 20 | 719 | 34 | 250 | 61 |
| 30 Jun 20 | 700 | 42 | 239 | 50 |
| 31 Mar 20 | 635 | 24 | 227 | 47 |
| 31 Dec 19 | 569 | 7 | 215 | 45 |
| 30 Sep 19 | 564 | 10 | 209 | 45 |
| 30 Jun 19 | 560 | 13 | 204 | 46 |
| 31 Mar 19 | 550 | 19 | 194 | 45 |
| 31 Dec 18 | 540 | 25 | 185 | 44 |
| 30 Sep 18 | 534 | 22 | 181 | 42 |
| 30 Jun 18 | 527 | 19 | 177 | 40 |
| 31 Mar 18 | 534 | 19 | 177 | 36 |
| 31 Dec 17 | 541 | 19 | 176 | 32 |
| 30 Sep 17 | 535 | 22 | 170 | 32 |
| 30 Jun 17 | 529 | 25 | 163 | 31 |
| 31 Mar 17 | 518 | 29 | 155 | 31 |
| 31 Dec 16 | 506 | 33 | 146 | 30 |
| 30 Sep 16 | 494 | 32 | 140 | 27 |
| 30 Jun 16 | 483 | 31 | 134 | 25 |
| 31 Mar 16 | 476 | 26 | 132 | 22 |
| 31 Dec 15 | 470 | 21 | 130 | 20 |
| 30 Sep 15 | 430 | 25 | 126 | 20 |
| 30 Jun 15 | 390 | 29 | 122 | 21 |
| 31 Mar 15 | 352 | 29 | 118 | 20 |
| 31 Dec 14 | 314 | 29 | 114 | 19 |
| 30 Sep 14 | 323 | 29 | 114 | 22 |
| 30 Jun 14 | 333 | 29 | 114 | 25 |
| 31 Mar 14 | 324 | 22 | 113 | 28 |
| 31 Dec 13 | 316 | 16 | 111 | 32 |
| 30 Sep 13 | 298 | 11 | 107 | 28 |
| 30 Jun 13 | 281 | 5 | 103 | 23 |
Quality Earnings: 4169 has high quality earnings.
Growing Profit Margin: 4169's current net profit margins (1.9%) are lower than last year (2.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4169's earnings have declined by 10.3% per year over the past 5 years.
Accelerating Growth: 4169's earnings growth over the past year (1.7%) exceeds its 5-year average (-10.3% per year).
Earnings vs Industry: 4169 earnings growth over the past year (1.7%) exceeded the Biotechs industry -6.1%.
Return on Equity
High ROE: 4169's Return on Equity (1.8%) is considered low.